Johnson & Johnson (JNJ.US) halts Phase 2 study of bladder cancer therapy TAR-200
AInvestTuesday, Oct 8, 2024 2:20 am ET
1min read
JNJ --

Johnson & Johnson (JNJ.US) said it has halted its Phase 2 study of TAR-200, a therapy for patients with muscle-invasive bladder cancer (MIBC), due to disappointing data. The study, known as SunRISe-2, was stopped after a mid-study analysis showed the treatment was not superior to standard-of-care chemotherapy, according to reports. However, the company said in a statement that it still plans to file for approval of TAR-200 as a single agent for non-muscle-invasive bladder cancer (NMIBC) in early 2025. The company added: "We remain confident in the sales potential of the TARIS platform of over $5 billion."

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.